Moleculin Biotech Past Earnings Performance

Past criteria checks 0/6

Moleculin Biotech's earnings have been declining at an average annual rate of -18.3%, while the Biotechs industry saw earnings growing at 7.7% annually.

Key information

-18.3%

Earnings growth rate

21.6%

EPS growth rate

Biotechs Industry Growth11.5%
Revenue growth raten/a
Return on equity-142.1%
Net Marginn/a
Next Earnings Update08 Nov 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Moleculin Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

LSE:0K2H Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 240-25918
31 Mar 240-271018
31 Dec 230-301019
30 Sep 230-261117
30 Jun 230-291120
31 Mar 230-301220
31 Dec 220-291219
30 Sep 220-251118
30 Jun 220-211016
31 Mar 220-18915
31 Dec 210-16814
30 Sep 210-16813
30 Jun 210-15813
31 Mar 210-21714
31 Dec 200-17713
30 Sep 200-19714
30 Jun 200-19713
31 Mar 200-10711
31 Dec 190-13611
30 Sep 190-12611
30 Jun 190-1069
31 Mar 190-14511
31 Dec 180-12510
30 Sep 180-1259
30 Jun 180-1359
31 Mar 180-1155
31 Dec 170-1045
30 Sep 170-843
30 Jun 170-733
31 Mar 170-432
31 Dec 160-421

Quality Earnings: 0K2H is currently unprofitable.

Growing Profit Margin: 0K2H is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 0K2H is unprofitable, and losses have increased over the past 5 years at a rate of 18.3% per year.

Accelerating Growth: Unable to compare 0K2H's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 0K2H is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.8%).


Return on Equity

High ROE: 0K2H has a negative Return on Equity (-142.15%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies